Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Psyence Biomedical Ltd (PBM) の株価収益率はいくらですか？
Psyence Biomedical Ltd の株価収益率は 2.3826 です。
Psyence Biomedical Ltd のCEOは誰ですか？
Mr. Marc Balkin は Psyence Biomedical Ltd の Chief Executive Officer で、2021 から在籍しています。
